Vulvar Cancer Treatment Market By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy and Supportive Care); By Cancer Stage (Early Stage Vulvar Cancer, Locally Advanced Vulvar Cancer, Metastatic or Recurrent Vulvar Cancer); By Route of Administration (Injectable, Intravenous, Oral, Topical); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals and Cancer Centers, Specialty Clinics, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Vulvar Cancer Treatment Shifts from Surgical Management Toward Biomarker-Guided Oncology

The Global Vulvar Cancer Treatment Market was valued at USD 800 million in 2025 and is projected to reach USD 1.35 billion by 2032, expanding at a CAGR of 7.85% during 2026–2032, according to Strategic Market Research.

 

Vulvar cancer is a rare gynecological malignancy affecting the external female genital tissues, with squamous cell carcinoma accounting for nearly 80%–90% of cases. The treatment market is primarily driven by surgical procedures, radiation therapy, chemoradiation, systemic therapies, and supportive care, with treatment selection strongly influenced by disease stage, patient age, tumor characteristics, and lymph-node involvement. The disease predominantly affects older women, with a median diagnosis age of approximately 70 years. In the United States, SEER estimates around 7,130 new cases and 1,750 deaths in 2026, highlighting the continued need for effective treatment strategies.

 

The stage of vulvar cancer at diagnosis plays a major role in determining treatment options and patient outcomes. When cancer is detected early and remains localized to the vulva, the 5-year survival rate is approximately 85.5%. If the cancer spreads to nearby lymph nodes or surrounding tissues (regional stage), survival decreases to about 51.4%. For cancers that have spread to distant organs (advanced stage), the 5-year survival rate falls to around 20.8%. These differences highlight the importance of early detection and timely treatment to improve patient outcomes.

 

Current therapeutic landscape remains limited, as no systemic therapy has a broad FDA approval specifically for vulvar cancer. Treatment primarily relies on surgery and radiation, while systemic options are adapted from other squamous cell cancers. HPV vaccines such as Gardasil and Gardasil 9 support prevention by reducing HPV-related precancerous vulvar lesions. Bleomycin sulfate has historical use in advanced disease, while chemotherapy agents including cisplatin and paclitaxel are commonly incorporated into clinical treatment pathways. For selected advanced tumors, pembrolizumab (Keytruda) provides an immunotherapy option under tumor-agnostic approvals for biomarkers such as MSI-H/dMMR or TMB-high status.

 

Overall, the vulvar cancer treatment market is evolving from primarily surgical management toward a more personalized oncology model. Future growth will depend on improved biomarker identification, development of vulvar-specific systemic therapies, and innovative treatment combinations that improve outcomes for patients with advanced or recurrent disease.

 

Key Vulvar Cancer Treatment Market Takeaways by Segment

Treatment Type

• Surgery: The leading segment held 45% of the market, representing USD 360 million in 2025, because surgical removal remains the primary curative pathway for localized and operable tumors.

• Radiation Therapy: The segment accounted for 22% and USD 176 million in 2025, supported by postoperative treatment and management of node-positive or locally advanced disease.

• Chemotherapy: The segment represented 15% and USD 120 million in 2025, with use concentrated in chemoradiation and recurrent or metastatic cancer.

• Immunotherapy: The fastest-growing treatment segment held 10% and USD 80 million in 2025, reflecting checkpoint-inhibitor use among selected patients with advanced disease.

• Targeted Therapy and Supportive Care: These treatments collectively accounted for 8% and USD 64 million in 2025, covering biomarker-directed options and management of pain, wounds, infections, and lymphedema.

 

Cancer Stage

• Early-Stage Vulvar Cancer: The leading stage segment captured 55% and USD 440 million in 2025 because most localized patients undergo surgery with appropriate lymph-node assessment.

• Locally Advanced Vulvar Cancer: The segment represented 30% and USD 240 million in 2025, reflecting the higher cost of chemoradiation, complex surgery, and reconstruction.

• Metastatic or Recurrent Vulvar Cancer: The fastest-growing stage segment held 15% and USD 120 million in 2025, supported by immunotherapy, molecular testing, and advanced systemic treatment.

 

Route of Administration

• Injectable: The leading segment accounted for 48% and USD 384 million in 2025, reflecting the extensive use of injected anticancer and supportive medicines.

• Intravenous: The segment represented 35% and USD 280 million in 2025, led by hospital-administered platinum chemotherapy, taxanes, and checkpoint inhibitors.

• Oral: The segment held 12% and USD 96 million in 2025, with growth linked to targeted treatments and supportive medicines.

• Topical: The segment contributed 5% and USD 40 million in 2025, mainly through localized and supportive applications rather than treatment of advanced invasive cancer.

 

Distribution Channel

• Hospital Pharmacies: The leading channel controlled 60% and USD 480 million in 2025 because most anticancer treatments are delivered through hospitals and comprehensive cancer centers.

• Specialty Pharmacies: The segment accounted for 22% and USD 176 million in 2025, supporting access to complex oncology medicines and reimbursement services.

• Retail Pharmacies: The channel represented 12% and USD 96 million in 2025, primarily supplying oral and supportive medicines.

• Online Pharmacies: The segment held 6% and USD 48 million in 2025, with participation concentrated in eligible oral and supportive-care prescriptions.

 

End User

• Hospitals and Cancer Centers: The leading segment accounted for 70% and USD 560 million in 2025 because treatment requires multidisciplinary oncology, surgery, radiation, pathology, and infusion capabilities.

• Specialty Clinics: The segment represented 20% and USD 160 million in 2025, supported by outpatient oncology treatment, follow-up, and survivorship care.

• Research Institutions: The segment held 10% and USD 80 million in 2025, reflecting clinical trials and biomarker-directed therapeutic research.

 

Geography

• North America: The leading region held 42% and USD 336 million in 2025, supported by advanced oncology infrastructure, specialist treatment centers, molecular testing, and access to newer therapies.

• Europe: The region accounted for 30% and USD 240 million in 2025, reflecting established gynecologic oncology and radiotherapy systems.

• Asia Pacific: The fastest-growing region represented 20% and USD 160 million in 2025, supported by improving diagnosis and oncology investment.

• Latin America: The region held 5% and USD 40 million in 2025, with treatment concentrated in major cancer centers.

• Middle East and Africa: The region accounted for 3% and USD 24 million in 2025, reflecting gradual expansion of specialist oncology and radiotherapy services.

 

Surgery Leads While Immunotherapy Creates the Fastest Treatment Expansion

Leading Segment—Surgery: Surgery accounted for a 45% share of the Vulvar Cancer Treatment Market, representing USD 360 million in 2025, and is projected to expand at a CAGR of 6.9% during 2026–2032. It leads because surgical removal remains the principal curative treatment for localized and operable vulvar cancer. Wide local excision and partial vulvectomy are increasingly preferred when adequate margins can be achieved, while radical vulvectomy remains necessary for extensive disease. Sentinel lymph-node biopsy also supports segment revenue through surgical mapping, nuclear medicine, pathology, and hospital services while reducing reliance on complete groin lymph-node dissection.

Fastest-Growing Segment—Immunotherapy: Immunotherapy held a 10% share, valued at USD 80 million in 2025, and is projected to record the highest CAGR of 14.5%. Growth is concentrated in recurrent, metastatic, and unresectable disease, where surgery and conventional chemotherapy provide limited options. Merck’s Keytruda (pembrolizumab) can be considered for patients meeting applicable tumor-agnostic indications, such as MSI-H/dMMR or TMB-high solid tumors. Continued evaluation of checkpoint inhibitors with chemotherapy and radiation could expand treatment eligibility, duration, and per-patient pharmaceutical expenditure.

 

Early-Stage Procedures Anchor Revenue While Recurrent Disease Increases High-Value Care

Leading Segment—Early-Stage Vulvar Cancer: Early-stage disease captured a 55% share, equivalent to USD 440 million in 2025, and is forecast to grow at a CAGR of 6.8%. This position reflects the large proportion of patients diagnosed while the tumor remains localized and potentially curable through surgery. Segment expenditure includes tumor excision, sentinel lymph-node mapping, specialist pathology, reconstruction, hospitalization, and postoperative surveillance. Adoption of conservative surgery lowers morbidity but increases the importance of precise staging and specialized multidisciplinary care.

Fastest-Growing Segment—Metastatic or Recurrent Vulvar Cancer: This segment accounted for a 15% share, representing USD 120 million in 2025, and is projected to expand at a CAGR of 12.8%. These patients require higher-value care involving repeat imaging, molecular profiling, systemic chemotherapy, checkpoint inhibitors, palliative radiation, and supportive treatment. Recurrence can be difficult to manage because previous surgery or radiation may restrict subsequent local treatment. Limited chemotherapy response and poor survival in distant disease create the strongest opening for biomarker-guided therapies and clinical-trial participation.

 

Injectable Treatment Dominates While Oral Targeted Options Expand

Leading Segment—Injectable: Injectable therapies held a 48% market share, valued at USD 384 million in 2025, and are expected to grow at a CAGR of 8.1%. The segment leads because treatment frequently involves clinician-administered chemotherapy, immunotherapy, antiemetics, analgesics, growth factors, and other supportive agents. Injectable delivery also allows hospitals to control dosing, monitor toxicity, and coordinate medicines with surgery or radiation. Its market position is closely connected to infusion capacity and specialist oncology infrastructure.

Fastest-Growing Segment—Oral: Oral therapies represented a 12% share, valued at USD 96 million in 2025, and are forecast to grow at a CAGR of 10.2%. Their current contribution is smaller because surgery, radiation, and infused systemic treatments dominate vulvar cancer care. Expansion is expected through orally administered targeted therapies used in molecularly selected patients and supportive medicines that can be taken outside treatment centers. Oral delivery may reduce infusion visits, but adoption will depend on stronger vulvar-specific evidence, appropriate biomarkers, and reimbursement.

 

Hospital Pharmacies Control Treatment Delivery as Specialty Access Expands

Leading Segment—Hospital Pharmacies: Hospital pharmacies controlled a 60% share of the market, representing USD 480 million in 2025, and are projected to expand at a CAGR of 7.3%. Vulvar cancer treatment is strongly hospital-centered because patients may require surgery, chemoradiation, infusion therapy, reconstruction, and inpatient complication management. Hospital pharmacies prepare cytotoxic medicines, verify oncology dosing, manage cold-chain products, and supply supportive drugs used during complex treatment. Their position is reinforced by the concentration of care in comprehensive cancer centers.

Fastest-Growing Segment—Specialty Pharmacies: Specialty pharmacies held a 22% share, valued at USD 176 million in 2025, and are expected to grow at a CAGR of 9.5%. These providers assist with high-cost oncology medicines, insurance authorization, patient-support programs, treatment monitoring, and delivery of eligible oral therapies. Their role will expand if molecularly targeted and immunotherapy-based treatment becomes available to a broader biomarker-selected population. Specialty pharmacies can also help coordinate access where products require complex reimbursement or safety management.

 

Multidisciplinary Cancer Centers Lead While Outpatient Specialty Care Gains Share

Leading Segment—Hospitals and Cancer Centers: Hospitals and cancer centers accounted for a 70% share, equivalent to USD 560 million in 2025, and are projected to grow at a CAGR of 7.4%. These institutions lead because vulvar cancer care often requires gynecologic oncologists, medical oncologists, radiation oncologists, reconstructive surgeons, nuclear-medicine teams, and specialist pathologists. Their integrated infrastructure supports surgery, sentinel-node assessment, chemoradiation, infusion therapy, molecular testing, and management of postoperative complications. Complex and advanced cases are therefore concentrated in major cancer centers rather than community practices.

Fastest-Growing Segment—Specialty Clinics: Specialty clinics represented a 20% share, valued at USD 160 million in 2025, and are forecast to expand at a CAGR of 9.1%. Their growth reflects the movement of appropriate infusion services, postoperative reviews, surveillance, wound management, lymphedema treatment, and survivorship care into outpatient settings. Gynecologic oncology and radiation clinics can reduce hospital resource use while maintaining specialist oversight. However, radical surgery and complex chemoradiation will remain concentrated in comprehensive hospitals.

 

North America Leads as Asia Pacific Expands Comprehensive Oncology Capacity

Leading Region—North America: North America captured a 42% share of the Vulvar Cancer Treatment Market, representing USD 336 million in 2025, and is expected to grow at a CAGR of 7.2%. The region leads because the United States has established gynecologic oncology networks, advanced radiation infrastructure, molecular testing, specialist pathology, and access to checkpoint inhibitors and clinical trials. High treatment expenditure per patient and the concentration of complex cases in comprehensive cancer centers support regional revenue across pharmaceuticals, surgery, diagnostics, radiotherapy, and supportive care.

Fastest-Growing Region—Asia Pacific: Asia Pacific held a 20% share, valued at USD 160 million in 2025, and is projected to register the fastest regional CAGR of 10.2%. China, Japan, India, South Korea, and Australia are expanding oncology capacity, radiotherapy access, pathology services, and specialist referral networks. Large metropolitan cancer centers increasingly provide multimodality treatment and advanced diagnostics, although access remains uneven outside major cities. Continued hospital investment and broader availability of systemic therapies will increase the proportion of diagnosed patients receiving comprehensive treatment.

 

Immunotherapy and Precision Radiotherapy Define Competitive Leadership

The three best-positioned companies are Merck & Co., Varian—a Siemens Healthineers company—and Elekta. Merck has the strongest pharmaceutical relevance through immunotherapy, while Varian and Elekta hold important positions in radiation systems used for postoperative, definitive, and chemoradiation treatment. This ranking reflects direct relevance to the vulvar cancer pathway rather than disclosed company-level revenue from this rare cancer.

Merck & Co.—Leading Pharmaceutical Company

Merck holds the strongest pharmaceutical position through Keytruda (pembrolizumab), an anti-PD-1 checkpoint inhibitor. The drug blocks signals that cancer cells use to suppress immune activity, allowing immune cells to recognize and attack susceptible tumors. Keytruda does not have a broad FDA indication specifically for vulvar cancer, but selected patients may qualify through applicable tumor-agnostic indications, including MSI-H/dMMR or TMB-high unresectable or metastatic solid tumors.

Merck also has the most substantial prospective immunotherapy evidence in advanced vulvar squamous cell carcinoma. KEYNOTE-158 evaluated pembrolizumab in 101 previously treated patients and reported a 10.9% objective response rate, with responses lasting a median of 20.4 months among responders. Although only a minority benefited, the potential for durable disease control gives Merck the clearest position in the fastest-growing immunotherapy segment and strengthens the commercial role of molecular testing.

Varian, a Siemens Healthineers Company—Leading Precision Radiotherapy Provider

Varian is a leading technology provider for the radiation component of vulvar cancer treatment. Its portfolio includes TrueBeam and Halcyon treatment-delivery systems, Ethos adaptive therapy, Eclipse treatment-planning software, HyperSight imaging, ARIA oncology information systems, and BRAVOS and GammaMedplus brachytherapy platforms. These technologies can support postoperative radiation, regional nodal treatment, definitive chemoradiation, and selected recurrent-disease procedures.

Varian’s competitive advantage comes from integrating simulation, treatment planning, image guidance, dose delivery, patient monitoring, and oncology workflow management. This is relevant to vulvar cancer because tumors and regional lymph nodes are located close to the bladder, rectum, bowel, and other sensitive tissues. Precise planning can maintain tumor coverage while limiting unnecessary exposure, positioning Varian strongly within hospitals and comprehensive cancer centers investing in advanced radiotherapy infrastructure.

Elekta—Leading Gynecologic Radiotherapy and Brachytherapy Company

Elekta has a strong position through linear accelerators, adaptive radiotherapy, treatment-planning technologies, and gynecologic brachytherapy systems. Its portfolio includes Elekta Unity, Elekta Evo, Versa HD, and brachytherapy solutions designed to help clinicians adjust radiation according to tumor position and surrounding pelvic anatomy. These systems are relevant to patients receiving postoperative radiation or definitive chemoradiation for locally advanced disease.

Elekta differentiates itself through MR-guided and CT-guided adaptive treatment, which allows clinical teams to account for anatomical changes between treatment sessions. Its brachytherapy and electronic brachytherapy technologies also support targeted radiation delivery while protecting surrounding organs. The company’s combination of equipment, software, training, and service contracts provides recurring commercial exposure beyond the initial installation.

Other Relevant Companies

• Bristol Myers Squibb: Participates through Opdivo (nivolumab), but the limited number of vulvar cancer patients studied prevents it from holding a leading disease-specific position.

• Roche: Contributes through Avastin (bevacizumab) and oncology diagnostics, although vulvar cancer use relies mainly on extrapolated cervical cancer evidence and limited clinical experience.

• Regeneron and Sanofi: Are evaluating Libtayo (cemiplimab) in advanced vulvar cancer strategies, but the therapy remains investigational for this specific indication.

• Johnson & Johnson MedTech: Supplies surgical instruments, energy devices, sutures, and wound-closure products, but these form a supporting portfolio rather than a dedicated vulvar cancer franchise.

• Stryker: Participates through operating-room technologies, surgical instruments, patient-positioning systems, and wound-management products without a disease-specific treatment portfolio.

• Medtronic: Supports vulvar cancer procedures through electrosurgical, energy, monitoring, and perioperative technologies but does not hold a leading therapeutic position.

 

Future Outlook and Commercial Opportunity Landscape – Vulvar Cancer Treatment Market

The future growth of the Vulvar Cancer Treatment Market will be driven not by a large increase in patient numbers, but by advances in precision oncology, targeted therapies, and improved treatment options for recurrent and advanced disease. Since vulvar cancer is a rare cancer with limited approved drug options, a major opportunity exists for companies developing therapies specifically designed for vulvar squamous cell carcinoma instead of relying mainly on treatments adapted from other cancers.

A key growth area is the expansion of immunotherapy and combination treatments. Current checkpoint inhibitors benefit only a limited group of biomarker-selected patients, creating demand for therapies that can improve response rates. Future opportunities include combining immune checkpoint inhibitors with chemotherapy, radiation, vaccines, antibody-based therapies, and other immune-targeting approaches to improve outcomes in advanced and metastatic disease.

Another important opportunity lies in biomarker testing and companion diagnostics. As treatment becomes more personalized, identifying patients based on markers such as MSI-H, mismatch repair deficiency, tumor mutational burden, HPV status, and immune-related signatures will become increasingly important. Wider use of molecular profiling and next-generation sequencing could help physicians select the most effective therapies and expand access to precision treatments.

Surgical innovation will remain central to vulvar cancer care, but the focus is shifting toward less invasive and function-preserving procedures. Advances in sentinel lymph-node biopsy, robotic-assisted surgery, surgical navigation, and improved reconstruction techniques may help reduce treatment complications while maintaining cancer control. Similarly, radiation oncology presents opportunities through advanced technologies such as adaptive radiotherapy, image-guided treatment, and AI-assisted radiation planning to improve accuracy and reduce toxicity.

Geographically, emerging markets, particularly in Asia Pacific and developing healthcare systems, represent long-term growth opportunities as cancer screening, diagnostic infrastructure, and specialist care networks improve. However, adoption will depend on affordability, healthcare access, and availability of specialized oncology services.

Overall, the Vulvar Cancer Treatment Market is expected to transition from a primarily surgery-focused model toward a personalized, biomarker-driven oncology ecosystem. Companies that develop disease-specific therapies, improve patient selection through diagnostics, and deliver safer, more effective treatment approaches will be best positioned to capture future market opportunities in this underserved cancer segment.

 

Vulvar Cancer Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 800 Million
Revenue Forecast in 2032	USD 1.35 Billion
Overall Growth Rate	CAGR of 7.85% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Cancer Stage, By Route of Administration, By Distribution Channel, By End User, By Geography
By Treatment Type	Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy and Supportive Care
By Cancer Stage	Early-Stage Vulvar Cancer, Locally Advanced Vulvar Cancer, Metastatic or Recurrent Vulvar Cancer
By Route of Administration	Injectable, Intravenous, Oral, Topical
By Distribution Channel	Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
By End User	Hospitals and Cancer Centers, Specialty Clinics, Research Institutions
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Mexico, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	Adoption of precision oncology, expansion of immunotherapy and combination treatments, increasing biomarker testing, advances in function-preserving surgery, investment in adaptive radiotherapy, and improving specialist oncology access
Customization Option	Available upon request